MA45155B1 - Procédés de préparation d'oligomères morpholino de phosphorodiamidate - Google Patents

Procédés de préparation d'oligomères morpholino de phosphorodiamidate

Info

Publication number
MA45155B1
MA45155B1 MA45155A MA45155A MA45155B1 MA 45155 B1 MA45155 B1 MA 45155B1 MA 45155 A MA45155 A MA 45155A MA 45155 A MA45155 A MA 45155A MA 45155 B1 MA45155 B1 MA 45155B1
Authority
MA
Morocco
Prior art keywords
phosphorodiamidate
processes
preparation
oligomer
morpholino oligomers
Prior art date
Application number
MA45155A
Other languages
English (en)
Other versions
MA45155A (fr
Inventor
Bao Cai
Mitchell MARTINI
Katie THOMAS
Ross SHIMABUKU
Original Assignee
Sarepta Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics, Inc. filed Critical Sarepta Therapeutics, Inc.
Publication of MA45155A publication Critical patent/MA45155A/fr
Publication of MA45155B1 publication Critical patent/MA45155B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/062—Organo-phosphoranes without P-C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des procédés de préparation d'un oligomère (par exemple, un oligomère morpholino). Les procédés de synthèse décrits ici peuvent être avantageux pour la mise à l'échelle de la synthèse d'oligomères tout en maintenant le rendement global et la pureté d'un oligomère synthétisé.
MA45155A 2016-05-24 2017-05-24 Procédés de préparation d'oligomères morpholino de phosphorodiamidate MA45155B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662340953P 2016-05-24 2016-05-24
US201662357134P 2016-06-30 2016-06-30
EP17731337.6A EP3464306B1 (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères morpholino de phosphorodiamidate
PCT/US2017/034284 WO2017205513A1 (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères morpholino de phosphorodiamidate

Publications (2)

Publication Number Publication Date
MA45155A MA45155A (fr) 2019-04-10
MA45155B1 true MA45155B1 (fr) 2024-06-28

Family

ID=59078166

Family Applications (2)

Application Number Title Priority Date Filing Date
MA71469A MA71469A (fr) 2016-05-24 2017-05-24 Procédé de préparation d'oligomères morpholino de phosphorodiamidate
MA45155A MA45155B1 (fr) 2016-05-24 2017-05-24 Procédés de préparation d'oligomères morpholino de phosphorodiamidate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA71469A MA71469A (fr) 2016-05-24 2017-05-24 Procédé de préparation d'oligomères morpholino de phosphorodiamidate

Country Status (28)

Country Link
US (3) US10961262B2 (fr)
EP (2) EP3464306B1 (fr)
JP (1) JP6987081B2 (fr)
KR (1) KR102504759B1 (fr)
CN (1) CN109311920B (fr)
AU (1) AU2017271524B2 (fr)
BR (1) BR112018074270B1 (fr)
CA (1) CA3024182A1 (fr)
CO (1) CO2018013827A2 (fr)
DK (1) DK3464306T3 (fr)
ES (1) ES2987586T3 (fr)
FI (1) FI3464306T3 (fr)
HR (1) HRP20240583T1 (fr)
HU (1) HUE066393T2 (fr)
IL (1) IL263033B2 (fr)
LT (1) LT3464306T (fr)
MA (2) MA71469A (fr)
MD (1) MD3464306T2 (fr)
MX (1) MX383656B (fr)
PL (1) PL3464306T3 (fr)
PT (1) PT3464306T (fr)
RS (1) RS65504B1 (fr)
SA (1) SA518400462B1 (fr)
SG (1) SG11201809499UA (fr)
SI (1) SI3464306T1 (fr)
SM (1) SMT202400183T1 (fr)
TW (1) TWI737736B (fr)
WO (1) WO2017205513A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
SG10202101834QA (en) * 2016-05-24 2021-04-29 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
MX383656B (es) 2016-05-24 2025-03-14 Sarepta Therapeutics Inc Procesos para preparar oligómeros de morfolino fosforodiamidato.
SG10202101830WA (en) * 2016-05-24 2021-04-29 Sarepta Therapeutics Inc Processes for preparing oligomers
IL263044B2 (en) 2016-05-24 2024-06-01 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
CN109152775B (zh) * 2016-06-30 2022-04-26 萨勒普塔医疗公司 制备磷酸二酰胺吗啉代寡聚物的方法
CN109152792B (zh) * 2016-06-30 2021-09-14 萨勒普塔医疗公司 制备磷酸二酰胺吗啉代寡聚物的方法
MA49986A (fr) 2017-09-25 2020-07-01 Massachusetts Inst Technology Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
JP7611825B2 (ja) 2018-08-02 2025-01-10 ダイン セラピューティクス，インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
CN109704980B (zh) * 2019-02-16 2022-05-13 安徽大学 一种(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的制备方法
EP4123023A4 (fr) * 2020-03-16 2024-07-17 National University Corporation Tokyo Medical and Dental University Acide hétéro-nucléique contenant un acide nucléique morpholino
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
CN117980006A (zh) 2021-07-09 2024-05-03 达因疗法公司 用于治疗肌养蛋白病的肌肉靶向复合物和制剂
CN118201640A (zh) * 2021-11-01 2024-06-14 达因疗法公司 用于治疗肌养蛋白病的肌肉靶向复合物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
WO1986005519A1 (fr) 1985-03-15 1986-09-25 James Summerton Reactif et procede d'analyse de polynucleotides
DE68914843T2 (de) 1988-09-01 1994-11-10 Risoe Forskningscenter Peptid-synthese und fester träger zur verwendung dabei.
CA2180253A1 (fr) 1993-12-29 1995-07-06 Atsushi Akahane Compose pyrazolopyridine antagoniste de l'adenosine
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
WO2001083740A2 (fr) 2000-05-04 2001-11-08 Avi Biopharma, Inc. Composition anti-sens a region d'epissage et methode associee
WO2003020739A2 (fr) 2001-09-04 2003-03-13 Exiqon A/S Compositions d'acides nucleiques verrouilles et utilisations
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
AU2003291682A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US7759513B2 (en) 2003-02-21 2010-07-20 Nigu Chemie Gmbh Photolabile protective groups for improved processes to prepare oligonucleotide arrays
PL1766010T3 (pl) 2004-06-28 2011-07-29 Univ Western Australia Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US9371348B2 (en) 2006-11-27 2016-06-21 The Trustees Of The University Of Pennsylvania Photocleavable oligonucleotide and uses thereof
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
DK2207779T3 (da) 2007-11-15 2014-07-14 Sarepta Therapeutics Inc Fremgangsmåde til syntese af morpholinooligomerer
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
JP2012523225A (ja) 2009-04-10 2012-10-04 アソシアシオン・アンスティテュ・ドゥ・ミオロジー 疾患の処置のためのトリシクロ−ｄｎａアンチセンスオリゴヌクレオチド、組成物及び方法
BR122023023194A2 (pt) 2009-11-12 2023-12-26 The University Of Western Australia Oligonucleotídeo antissentido, composição e respectivo uso
KR102182663B1 (ko) * 2010-05-28 2020-11-25 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
TWI463423B (zh) * 2010-05-28 2014-12-01 Poynt Corp 用以針對基於三維形狀之廣告系統使用位置資訊的方法
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
DK2623507T3 (da) 2010-09-30 2017-01-02 Nippon Shinyaku Co Ltd Morpholinonukleinsyrederivat
CA2826836A1 (fr) * 2011-02-08 2012-08-16 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Oligonucleotides antisens
US9920084B2 (en) 2011-08-23 2018-03-20 The Royal Institution For The Advancement Of Learning/Mcgill University Ionic tags for synthesis of oligoribonucleotides
EP2581448B1 (fr) 2011-10-13 2015-01-28 Association Institut de Myologie ADN tricyclo-phosphorothioate
JP2015500204A (ja) 2011-11-18 2015-01-05 サレプタ セラピューティクス， インコーポレイテッド 機能的に修飾されたオリゴヌクレオチドおよびそのサブユニット
AU2012345638C1 (en) 2011-11-30 2018-10-18 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
CA3132111A1 (fr) * 2011-12-28 2013-07-04 Nippon Shinyaku Co., Ltd. Acides nucleiques antisens pour saut d'exon 55 du gene humain de la dystrophine
EP2820155B1 (fr) 2012-02-28 2017-07-26 Population Genetics Technologies Ltd. Procédé de fixation d'une contre-séquence à un échantillon d'acides nucléiques
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
HRP20190382T1 (hr) * 2013-03-14 2019-04-19 Sarepta Therapeutics, Inc. Pripravci koji preskaču ekson za liječenje mišićne distrofije
EA202090946A3 (ru) * 2013-03-14 2021-07-30 Сарепта Терапьютикс, Инк. Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии
NZ631289A (en) 2013-03-15 2017-08-25 Sarepta Therapeutics Inc Improved compositions for treating muscular dystrophy
US8999152B2 (en) * 2013-03-15 2015-04-07 Uop Llc Process and apparatus for recovering and blending hydroprocessed hydrocarbons and composition
EP3015467B1 (fr) * 2013-05-24 2024-12-04 Ajinomoto Co., Inc. Procédé de fabrication de morpholino-oligonucléotide
IL263044B2 (en) 2016-05-24 2024-06-01 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
SG10202101830WA (en) * 2016-05-24 2021-04-29 Sarepta Therapeutics Inc Processes for preparing oligomers
SG10202101834QA (en) * 2016-05-24 2021-04-29 Sarepta Therapeutics Inc Processes for preparing phosphorodiamidate morpholino oligomers
MX383656B (es) 2016-05-24 2025-03-14 Sarepta Therapeutics Inc Procesos para preparar oligómeros de morfolino fosforodiamidato.
LT3554553T (lt) 2016-12-19 2022-08-25 Sarepta Therapeutics, Inc. Egzoną šalinantys oligomero konjugatai nuo raumenų distrofojos

Also Published As

Publication number Publication date
US20250276988A1 (en) 2025-09-04
CO2018013827A2 (es) 2018-12-28
CA3024182A1 (fr) 2017-11-30
ES2987586T3 (es) 2024-11-15
US12258362B2 (en) 2025-03-25
EP4406600A2 (fr) 2024-07-31
SMT202400183T1 (it) 2024-07-09
EP3464306A1 (fr) 2019-04-10
CN109311920B (zh) 2021-11-09
US10961262B2 (en) 2021-03-30
TW201825506A (zh) 2018-07-16
AU2017271524B2 (en) 2021-06-24
HRP20240583T1 (hr) 2024-07-19
MD3464306T2 (ro) 2024-08-31
SG11201809499UA (en) 2018-12-28
SA518400462B1 (ar) 2022-06-12
HUE066393T2 (hu) 2024-07-28
IL263033B2 (en) 2023-02-01
CN109311920A (zh) 2019-02-05
BR112018074270A2 (pt) 2019-03-12
TWI737736B (zh) 2021-09-01
MX2018014162A (es) 2019-04-01
BR112018074270B1 (pt) 2021-02-02
EP3464306B1 (fr) 2024-03-27
LT3464306T (lt) 2024-05-10
PT3464306T (pt) 2024-05-17
US20190276480A1 (en) 2019-09-12
EP4406600A3 (fr) 2024-10-30
IL263033B (en) 2022-10-01
MA45155A (fr) 2019-04-10
AU2017271524A1 (en) 2018-11-15
RS65504B1 (sr) 2024-06-28
PL3464306T3 (pl) 2024-07-22
FI3464306T3 (fi) 2024-05-16
KR102504759B1 (ko) 2023-02-28
JP6987081B2 (ja) 2021-12-22
IL263033A (en) 2018-12-31
MX383656B (es) 2025-03-14
WO2017205513A1 (fr) 2017-11-30
US20220340605A1 (en) 2022-10-27
KR20190013844A (ko) 2019-02-11
DK3464306T3 (da) 2024-05-21
JP2019523754A (ja) 2019-08-29
SI3464306T1 (sl) 2024-08-30
MA71469A (fr) 2025-04-30

Similar Documents

Publication Publication Date Title
MA45154B1 (fr) Procédés de préparation d'oligomères
SA518400462B1 (ar) عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو
MX390906B (es) Procesos para preparar oligómeros de morfolino fosforodiamidato.
ZA202403308B (en) An efficient new process for synthesis of 2-amino-5-chloro-n-,3-dimethylbenzamide
SA518400463B1 (ar) عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو
WO2016141296A8 (fr) Inhibiteurs de kinases tricycliques de melk et procédés d'utilisation
TN2018000393A1 (en) Pegylated carfilzomib compounds
MX2025000971A (es) Proceso para la sintesis del acido (s)-3-amino-4-(difluorometilenil)ciclopent-1-eno-1-carboxilico
MA68842B1 (fr) Procédé de conjugaison de cys-mabs
WO2018039629A3 (fr) Acides nucléiques sphériques micellaires obtenus à partir de matrices thermosensibles sans trace
PH12021550639A1 (en) Synthesis of 2`-Fluoro-6`-Methylene-Carbocyclic Adenosine (FMCA) and 2`-Fluoro-6`-Methylene-Carbocyclic Guanosine (FMCG)
JOP20210157B1 (ar) تخليق 3-ميثيل-1، 2، 4-ثياديازول-5-كربوهيدرازيد أو ميثيل-d3 مُعَالَج بالديوتيريوم منه
CO2018013831A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
MX2019001053A (es) Inhibidores de antigeno de la membrana especifico para la prostata (psma) quelados.
UY31460A1 (es) Procedimiento de preparacion de compuestos morfinicos
MY140739A (en) 2, 6-quinolinyl derivatives, processes for preparing them and their uses
EP3672601A4 (fr) Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide
MX2022006142A (es) Proceso para la sintesis de (3-cloro-2-piridil)hidrazina.
DE60329721D1 (de) Regiospezifische synthese von nikotinderivaten
WO2019191363A3 (fr) Synthèse rapide d'oseltamivir et de composés apparentés par réaction de diazidation-diamidification directe d'oléfines
EP4043425A4 (fr) Procédé de préparation de 1,3-cyclopentanediol
EA200800466A1 (ru) Способ получения эрбумина периндоприла
BR112021006669A2 (pt) métodos para síntese de oxipicolinamidas
IN2013CH05430A (fr)
ITTO20030474A1 (it) Procedimento per la preparazione di dexloxiglumide